Skip to content
International Academy for Clinical Hematology (IACH) Logo
  • About
    • Mission
    • Bylaws
    • Topics
    • Membership
    • Founders
    • Conflict of Interest Policy
    • Clinical Hematology International
    • IACH Supporters
    • Terms of Service
    • Contact
    • Meetings
      • Controversies in Multiple Myeloma (COMy)
      • Controversies in MDS and AML (COMydAL)
      • Controversies in Lymphoma (COLYM)
      • MPNControversies & Debates (MPN Co&D)
      • Annual Meeting of the IACH
      • Summit on Immunotherapy and Cellular Therapy in Cancer (ICTC)
  • Webinars
    • IACH for Nurses
    • Webinars
    • Post-Cong. webinars
    • Special webinars
  • IACH Giants
  • Journal Club
  • IACH News
    • IACH CAR-T News
  • Junior Club
  • The Innovation and R&D Podium

Dr. Doris Hansen- Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium

Home/All/Dr. Doris Hansen- Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium
Previous Next

Dr. Doris Hansen- Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium

By efrat|2023-01-22T07:12:06+00:00January 22nd, 2023|All|Comments Off on Dr. Doris Hansen- Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium

Share This Story, Choose Your Platform!

FacebookTwitterRedditLinkedInWhatsAppTumblrPinterestVkEmail

About the Author: efrat

Related Posts

Dr. Oluwole Olalekan- Approval of Polatuzumab Vedotin Plus R-CHP in Previously Untreated DLBCL

Dr. Oluwole Olalekan- Approval of Polatuzumab Vedotin Plus R-CHP in Previously Untreated DLBCL

Dr. Bhagirathbhai Dholaria- Omisirge Allogeneic Cord Blood-Based Cell Therapy Approved to Reduce Risk of Infection Following Stem Cell Transplantation

Dr. Bhagirathbhai Dholaria- Omisirge Allogeneic Cord Blood-Based Cell Therapy Approved to Reduce Risk of Infection Following Stem Cell Transplantation

Dr. Paula Rodríguez Otero- Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma

Dr. Paula Rodríguez Otero- Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma

Prof. Christoph Stein Thoeringer- Role of the Gut Microbiome in CAR-T cell Therapy

Prof. Christoph Stein Thoeringer- Role of the Gut Microbiome in CAR-T cell Therapy

Prof. Florent Malard- The First microbiota therapy approved by the US FDA

Prof. Florent Malard- The First microbiota therapy approved by the US FDA

About

The IACH, founded by an international group of physicians whose focus is to promote good clinical practice in the field of clinical hematology, is registered in England (Number: 14200227) under the Companies Act 2006.

In collaboration with:

Contact

International Academy for Clinical Hematology (IACH)
35 Ballards Lane
London N3 1XW
United-Kingdom
[email protected]
+44 203 291 1603

Copyright © 2022 International Academy for Clinical Hematology | All Rights Reserved
Page load link
Go to Top